The next investigational drug application…

is set to launch.

With the submission of an IND (investigational new drug application) to the ethics committee at the University of Basel, XBiotech is well on its way to starting a second phase I/II clinical trial.  This proposed trial, focusing on the treatment of type 2 diabetes, will be conducted in Switzerland under the direction of a leading expert in the field of Endocrinology and Diabetes.  Diabetes is a disease caused primarily by obesity, and unfortunately the incidence of obesity and diabetes continues to rise industrialized nations.  A chronic inflammatory response has also been observed in diabetes.  This process drives disease progression and the development of disease associated comorbidities.  Blocking the chronic inflammatory process that drives type 2 diabetes may provide a new and more effective treatment option for these patients.